Navigation Links
Bio-Pharma Industry Experts Deliver M&A Value Through Integration Excellence

CHAPEL HILL, N.C., April 28 /PRNewswire/ -- The biopharma mega-mergers that grabbed headlines last year - Roche + Genentech, Pfizer + Wyeth and Merck + Schering-Plough - are now in the critical post-integration period and the acquiring companies are finding out how well they planned and executed their integration plans. It's too early for final verdicts, but clearly one M&A issue that continues to create problems for the industry is the integration of corporate cultures.

A Best Practices, LLC study found while corporate culture was rated as a highly important risk-assessment factor for a successful integration, cultural assessments were rated as a less effective pre-integration planning activity due to accuracy. Experienced integration leaders develop specific processes and approaches to assess the culture of M&A targets and then continuously assess and monitor to ensure the cultures integrate along with operations, according to our report "M&A Integration Excellence: What Bio-Pharma Companies Need to Know."

To access the full report or download a complimentary copy of the report summary, go to

Understanding and managing cultural issues is just one of the topics addressed in the 107-page report, which utilizes benchmark metrics and executive insights to assess current trends and future directions of bio-pharmaceutical M&A activity. The study had 26 organizations participate, including such influential companies as Pfizer, Eli Lilly, Johnson & Johnson and Abbott.

Other key topic areas in the research include:

  • Structure for Integration
  • Pre-Integration Planning Activities
  • Integration Risk Management
  • Integration Functional Excellence
  • Communications Excellence
  • Understanding & Managing Cultural Issues
  • Post-Deal Closure Integration Activities
  • Trends in M&A Integration

The pace of merger and acquisition activity in the biopharma sector remains steady as organizations continue to seek external opportunities to grow their pipelines. This data-rich report addresses key M&A issues and identifies proven practices and key success factors in the merger & acquisition integration process among pharmaceutical and biotechnology companies.

The key points this study addresses are:

  • What are the keys to successful M&A integration planning?
  • What structure, processes and best practices lead to M&A integration excellence?
  • What are the key risk factors to assess and manage in the M&A integration process?
  • How is success of the M&A integration function best measured and represented?
  • What are the critical success factors and pitfalls in the integration process?

For more information on this report, contact Jeff Zimmer at or (919) 767-9180. To access the full report or download a complimentary copy of the report summary, go to


Best Practices, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. For more than 15 years, our highly credentialed research staff has conducted primary research exclusively for our Fortune 500 client base.

SOURCE Best Practices, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Northern Light Adds 4,000 Bio-Pharma, Health Sciences and General Business News and Journal Sources from EBSCO Publishing
2. Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase
3. Babson Executive Education Offers Bio-Pharma: Mastering the Business of Science
4. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
5. U.S. Meat Industry Will Respond to World Cancer Research Fund Report
6. Wedgewood Introduces Refresh(TM) Exchange-Program: Free Exchange of Expired Veterinary Compounded Medications Solves Key Industry Problem
7. EntreMed to Present at The New York Society of Security Analysts Industry Conference
8. GeoVax Labs, Inc. Selected by Georgia Bio as 2008 Deal of the Year Award Winner in Life Sciences Industry
9. Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
10. Industry Executives Finding Value in Shift of Scientific Publications
11. NeoStem Reports Positive Stem Cell Industry Research Trends From The Journal of the American Medical Association and Third Annual Stem Cell Summit
Post Your Comments:
(Date:11/30/2015)... , Nov. 30, 2015 Oramed Pharmaceuticals ... focused on the development of oral drug delivery systems, ... agreements valued at up to $50,000,000 with Hefei Tianhui Incubator of Technologies ... oral insulin capsule, ORMD-0801, in China ... Macau . The agreements were signed at ...
(Date:11/30/2015)... , Nov. 30, 2015   Nuance Communications, Inc. ... National Decision Support Company (NDSC) today jointly announced ... collaboration capabilities that utilize the American College of Radiology,s ... provider organizations to comply with current and emerging ... --> By combining clinical decision support, ...
(Date:11/30/2015)... 30, 2015  Hanger, Inc. (NYSE: HGR ) ... the terms of its previously announced consent solicitation (as ... $200,000,000 aggregate principal amount 7⅛% Senior Notes due 2018 ... consent fees payable pursuant to the Consent Solicitation, (ii) ... (iii) the expiration date of the Consent Solicitation.    ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... ... Stress, anxiety, illness, infection or even a need for eyeglasses can sometimes ... MD, a new pediatric neurosurgeon at Joe DiMaggio Children’s Hospital in Hollywood, Florida, said ... , “Bad headaches that don’t go away, that don’t have any other reason, ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... the driverless vehicle experience this summer, ushering in a new era of publicly ... driverless and electric shuttle, will continue to offer guests an up-close look at ...
(Date:11/30/2015)... ... November 30, 2015 , ... The presidential race normally deals with political issues ... it a national news story when Donald Trump makes disparaging remarks about Hillary Clinton’s ... more than anyone wants to admit when it comes to how people are viewed ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... course in Dallas, TX, on January 29 and 30, 2016. The course welcomes ... functions of their practices, to learn how to better succeed in the modern ...
(Date:11/30/2015)... ... 2015 , ... A novel class of antimicrobials that inhibits ... fighting methicillin-resistant Staphylococcus aureus (MRSA), one of the major drug-resistant bacterial pathogens, according ... analogs that target the functions of SecA, a central part of the general ...
Breaking Medicine News(10 mins):